Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FerroTrace and ICG Lymph Node Mapping in Colorectal Cancer
NCT05092750Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2021
- Primary completion
- Aug 2023
01
Overview
Phase 2, open-label trial, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Feasibility of Sentinel Lymph Node Mapping and Rate of Grade III or Greater Toxicity. Planned start Sep 2021; status: withdrawn.
Beyond the preview
Go deeper on NCT05092750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05092750.